This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of interferon beta-1a
MSMED_INTERFERONBETA1A
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
893 |
4. Check minimum number of events
Min. number of events
3
|
893 |
5. Include endpointsNone |
893 |
6. Filter based on genotype QC (FinnGen only) |
854 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of interferon beta-1a
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 854 | 684 | 170 |
| Unadjusted period prevalence (%) | 0.21 | 0.24 | 0.08 |
| Median age at first event (years) | 36.37 | 36.25 | 36.83 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 893
- Matched controls
- 8930
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BB01
ATC
amantadine; oral
94.7
307.7
262
39
N86
ICPC
Multiple sclerosis
326.6
307.7
330
16
L03AB07
ATC
interferon beta-1a; parenteral
+∞
307.7
893
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
31.5
307.7
534
403
L04AX07
ATC
dimethyl fumarate; oral
238.6
307.7
217
12
164
Kela drug reimbursment
Fingolimod
331.6
307.7
242
10
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
893
54
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
8258.4
307.7
861
29
H46
ICD-10 Finland
Optic neuritis
140.0
307.7
323
36
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
125.0
307.7
252
28
L04AA31
ATC
[U] teriflunomide
220.0
307.7
204
12
L03AX13
ATC
glatiramer acetate; parenteral
395.9
307.7
357
15
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
2090.0
307.7
782
30
109
Kela drug reimbursment
Multiple sclerosis
6228.7
307.7
857
34
L03AB08
ATC
interferon beta-1b; parenteral
150.7
281.2
140
11
M03BX01
ATC
baclofen; systemic
33.3
279.0
186
70
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
28.6
248.0
174
75
TAB00
NOMESCO Finland
Lumbar puncture
14.9
242.2
243
218
353
Kela drug reimbursment
Cladribine and fingolimod
302.5
213.1
209
9
G04BD09
ATC
trospium; oral
39.2
209.8
131
39
L04AA27
ATC
[U] fingolimod
424.0
203.7
197
6
XCK00
NOMESCO Finland
Perimetry
15.3
202.7
194
159
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
34.6
190.2
123
41
XA800
NOMESCO Finland
Neuropsychological investigation
12.6
184.1
201
202
N07XX09
ATC
[U] dimethyl fumarate
249.9
180.6
180
9
XKD06
NOMESCO Finland
Physiologic investigation of micturition
25.6
174.9
126
57
G04BD12
ATC
mirabegron; oral
10.1
173.0
226
290
XKD00
NOMESCO Finland
Uroflowmetry
10.1
152.8
194
238
N06BA07
ATC
modafinil; oral
66.1
152.2
84
14
ZX120
NOMESCO Finland
Intravenous
7.4
127.8
217
371
G04BD04
ATC
oxybutynin; oral, transdermal
11.5
121.8
135
136
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.4
115.6
230
459
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
41.5
113.3
69
18
G04BD07
ATC
tolterodine; oral
12.4
107.8
112
102
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
15.4
107.3
97
70
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.8
98.5
300
858
H02AB04
ATC
methylprednisolone; systemic
5.0
96.4
267
706
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
7.7
96.4
149
227
2AB04, ,
NOMESCO Finland
124.9
94.1
100
9
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
10.6
94.1
109
116
R1250
NOMESCO Finland
Evaluation of functional capability
11.8
92.2
98
92
N03AE01
ATC
clonazepam; systemic
7.6
91.4
141
214
XKC03
NOMESCO Finland
Water cystometry
12.4
91.3
94
84
TKC22
NOMESCO Finland
Catheterisation instruction
24.1
89.8
65
29
R20.2
ICD-10 Finland
Paraesthesia of skin
5.7
88.4
191
406
UKC02
NOMESCO Finland
Cystoscopy
5.7
87.1
190
407
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
459.7
85.6
84
*
G04BD08
ATC
solifenacin; oral
8.6
85.5
117
154
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.3
75.8
176
396
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
170.7
75.3
78
5
L04AK02
ATC
teriflunomide; oral
168.3
74.3
77
5
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
72.9
69
*
L04AE01
ATC
fingolimod; oral
744.9
71.1
69
*
XCD10
NOMESCO Finland
Electrophysiological examination of eye
12.0
67.3
70
63
R4150
NOMESCO Finland
Neuropsychological rehabilitation
17.2
65.5
55
34
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
20.2
61.9
48
25
Z2445
NOMESCO Finland
Psychologist
6.1
60.6
114
210
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.6
60.6
126
255
N03AX12
ATC
[U] gabapentin; oral
3.7
60.4
249
853
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.1
60.3
85
115
H53.2
ICD-10 Finland
Diplopia
8.5
59.6
80
102
G04BD11
ATC
fesoterodine; oral
13.8
59.3
56
43
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
317.5
59.0
59
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
10.1
57.5
67
71
4AA23, ,
NOMESCO Finland
195.1
53.6
55
*
R33
ICD-10 Finland
Retention of urine
7.6
53.3
79
113
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.6
52.9
141
351
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
281.9
52.7
53
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.4
51.8
91
156
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
13.3
49.8
48
38
R35
ICD-10 Finland
Polyuria
5.6
49.0
99
194
Z3226
NOMESCO Finland
Physiotherapist
3.2
46.6
237
910
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
62.5
45.9
53
9
Z3231
NOMESCO Finland
Registered nurse
2.8
44.7
316
1451
C10AC01
ATC
colestyramine; oral
7.5
43.7
65
93
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
16.7
43.7
37
23
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
9.6
43.4
52
57
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
7.3
42.9
65
95
SPAT1229
SPAT
Assessment of need for aid
5.6
41.9
84
163
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.4
40.3
108
268
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
16.8
40.2
34
21
J01EA01
ATC
trimethoprim; systemic
2.6
39.3
320
1562
L04AG12
ATC
ofatumumab; parenteral
+∞
38.8
37
*
R4120
NOMESCO Finland
Occupational therapy
4.2
38.4
112
296
N28
ICPC
Limited function/disability (N)
13.4
37.6
36
28
RF120, ,
NOMESCO Finland
14.7
37.5
34
24
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
14.2
35.8
33
24
N05CF01
ATC
zopiclone; oral
2.5
35.3
331
1711
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
6.4
34.0
58
96
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.9
33.7
109
310
N03AX16
ATC
[U] pregabalin
2.6
33.5
261
1232
N29
ICPC
Neurological sympt/complt other
8.2
32.6
44
56
TKC20
NOMESCO Finland
Catheterisation of bladder
4.8
32.3
76
169
L04AA40
ATC
cladribine; oral
117.7
31.9
34
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.2
31.9
91
236
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
49.5
31.8
38
8
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
31.4
30
*
L28
ICPC
Limited function/disability (L)
3.0
30.2
152
569
R4110
NOMESCO Finland
Physiotherapy
2.4
29.8
281
1438
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.9
29.6
166
659
R5110, ,
SPAT
4.4
29.6
77
186
N99
ICPC
Neurological disease other
11.9
29.3
30
26
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
107.0
28.8
31
*
N03AF01
ATC
carbamazepine; oral, rectal
4.4
28.7
76
186
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.5
27.0
99
305
XKD03
NOMESCO Finland
Urethral pressure profilometry
7.2
26.0
39
56
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.8
25.3
40
61
G50.0
ICD-10 Finland
Trigeminal neuralgia
6.3
25.2
43
71
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.5
24.8
63
149
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
24.4
149
615
G04CA02
ATC
tamsulosin; oral
3.3
24.3
99
326
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.4
24.1
94
301
A28
ICPC
Limited function/disability NOS
3.2
24.0
104
355
RF420, ,
NOMESCO Finland
8.3
24.0
32
40
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
26.7
22.8
31
12
H02AB07
ATC
prednisone; oral
2.6
22.6
147
625
Z50.1
ICD-10 Finland
Other physical therapy
4.0
22.4
65
170
J01CA08
ATC
pivmecillinam; oral
2.0
22.3
472
3216
U04
ICPC
Incontinence urine
4.7
22.2
53
119
RF410, ,
NOMESCO Finland
8.7
22.0
28
33
N02BF01
ATC
gabapentin; oral
2.9
20.8
106
396
U02
ICPC
Urinary frequency/urgency
2.5
20.5
143
627
U13
ICPC
Bladder symptom/complaint other
5.3
20.2
41
80
A06AD11
ATC
lactulose; oral
2.9
20.2
101
374
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
15.8
19.9
32
21
H53.1
ICD-10 Finland
Subjective visual disturbances
3.1
19.9
90
315
N06AA09
ATC
amitriptyline; systemic
2.8
19.7
104
396
N06AX16
ATC
venlafaxine; oral
2.2
19.7
197
1011
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
56.3
19.0
22
*
XF400
NOMESCO Finland
ECG with 12 standard connections
2.6
19.0
126
539
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
18.8
18
*
A02BC02
ATC
pantoprazole; systemic
1.9
18.8
602
4602
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
18.6
235
1318
N30.0
ICD-10 Finland
Acute cystitis
2.2
18.3
175
880
R15
ICD-10 Finland
Faecal incontinence
5.8
17.8
33
59
Z3229
NOMESCO Finland
Other healthcare associate professional
3.0
17.8
81
284
RS221, ,
NOMESCO Finland
6.2
17.4
30
50
L04AX01
ATC
azathioprine; systemic
3.5
17.4
62
187
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
21.4
17.4
25
12
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
15.2
17.2
28
19
M03BX02
ATC
tizanidine; oral
1.9
16.6
644
5128
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
173.1
16.5
17
*
G04CA01
ATC
alfuzosin; oral
3.3
16.1
64
207
N06AB04
ATC
citalopram; systemic
2.0
16.1
220
1261
359
Kela drug reimbursment
Mirabegroni
48.4
16.1
19
*
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
5.8
15.9
29
51
U07
ICPC
Urine symptom/complaint other
3.1
15.9
68
230
3419X
ICD-9 Finland
Other demyelinating diseases of central nervous system, Demyelinating disease of central nervous system, unspecified
162.7
15.5
16
*
SPAT1231
SPAT
Assessment of adjustments needed in living environment
12.6
15.4
27
22
Z2446
NOMESCO Finland
Social worker
2.8
15.4
80
302
N03AF02
ATC
oxcarbazepine; oral
3.6
15.3
51
147
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
16.4
15.3
24
15
SPAT1216
SPAT
Assessment of functional ability
2.5
15.1
101
432
G04BD10
ATC
darifenacin; oral
32.3
14.8
19
6
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
14.6
14
*
34099
ICD-8 Finland
Multiple sclerosis
+∞
14.6
14
*
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
5.5
14.6
28
52
L01BB04
ATC
cladribine; systemic
152.4
14.5
15
*
R32
ICD-10 Finland
Unspecified urinary incontinence
5.3
14.5
29
56
R42
ICD-10 Finland
Dizziness and giddiness
2.0
14.4
176
965
TPH04
NOMESCO Finland
Cathetrisation of vein
2.0
14.2
184
1030
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.3
14.0
113
526
N04BC05
ATC
pramipexole; oral
2.8
13.5
71
269
H47.2
ICD-10 Finland
Optic atrophy
26.2
13.4
18
7
G51.0
ICD-10 Finland
Bell palsy
4.2
13.3
35
85
KA1AE
NOMESCO Finland
Kidney ultrasound examination
4.9
13.1
29
61
U29
ICPC
Urinary symptom/complaint other
4.5
12.7
31
71
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.3
12.5
105
496
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
12.5
12
*
L04AX09
ATC
diroximel fumarate; oral
+∞
12.5
12
*
RS340, ,
NOMESCO Finland
131.8
12.5
13
*
36703
ICD-8 Finland
Inflammation of optic nerve and retina, Neuritis optica, retrobulbaris
131.8
12.5
13
*
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.1
12.4
52
174
XCK10
NOMESCO Finland
Photography of fundus of eye
2.6
12.1
75
309
U05
ICPC
Urination problems other
3.6
11.8
39
112
A06AC01
ATC
ispaghula (psylla seeds); oral
1.8
11.7
205
1260
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.1
11.5
49
165
G04BDXX, ,
ATC
121.5
11.4
12
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.7
11.0
308
2152
Z2221
NOMESCO Finland
Medical doctor
1.7
10.9
269
1818
R39.1
ICD-10 Finland
Other difficulties with micturition
4.8
10.8
24
51
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
18.1
10.7
16
9
G82.2
ICD-10 Finland
Paraplegia, unspecified
28.4
10.7
14
5
R03CA02
ATC
ephedrine; oral
60.7
10.6
12
*
NA7CM
NOMESCO Finland
Spine and spinal cord extensive MRI examination with 3 Tesla magnet
111.3
10.4
11
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.2
10.4
87
410
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
10.8
10.3
19
18
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
9.7
10.3
20
21
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
2.4
10.3
73
321
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
14.8
10.0
16
11
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
40.5
10.0
12
*
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
4.2
9.9
26
63
N30.9
ICD-10 Finland
Cystitis, unspecified
2.5
9.9
61
251
J01MA02
ATC
ciprofloxacin; systemic
1.6
9.8
293
2068
H04.10
ICD-10 Finland
Dry eye syndrome
2.0
9.7
115
620
N06AX21
ATC
duloxetine; oral
1.9
9.7
133
754
Z01.2
ICD-10 Finland
Dental examination
1.6
9.5
432
3353
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
2.7
9.4
51
197
H53.4
ICD-10 Finland
Visual field defects
4.4
9.4
23
53
A02BA02
ATC
ranitidine; systemic
1.8
9.2
138
804
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
5.1
9.1
19
38
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
15.8
9.0
14
9
K59.0
ICD-10 Finland
Constipation
2.9
9.0
43
155
H57.9
ICD-10 Finland
Disorder of eye and adnexa, unspecified
7.6
9.0
20
27
SPAT1325
SPAT
Vaccination
1.7
8.9
215
1432
Z43.5
ICD-10 Finland
Attention to cystostomy
24.3
8.9
12
5
K59.09
ICD-10 Finland
Constipation, unspecified
2.7
8.9
47
179
U71
ICPC
Cystitis/urinary infection other
2.3
8.9
67
303
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
2.6
8.6
50
200
N02BE01
ATC
paracetamol; systemic, rectal
1.8
8.6
773
6960
H57.1
ICD-10 Finland
Ocular pain
2.5
8.5
51
208
4AA36, ,
NOMESCO Finland
90.9
8.4
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.6
8.4
212
1426
ABD40
NOMESCO Finland
Implantation of spinal injection device
+∞
8.3
8
*
N18
ICPC
Paralysis/weakness
7.2
8.3
19
27
119
Kela drug reimbursment
Trigeminal neuralgia or glossofaryngeusneuralgia
14.6
8.2
13
9
L89
ICD-10 Finland
Decubitus ulcer and pressure area
7.6
8.2
18
24
U01
ICPC
Dysuria/painful urination
2.1
7.9
72
352
G04BE03
ATC
sildenafil; oral
10.9
7.8
14
13
A02BA04
ATC
nizatidine; systemic
2.5
7.7
50
211
U08
ICPC
Urinary retention
8.1
7.6
16
20
WW400
NOMESCO Finland
Plasmaferesis
25.2
7.6
10
*
N04BD01
ATC
selegiline; oral
7.2
7.5
17
24
M01AE01
ATC
ibuprofen; systemic, rectal
2.3
7.5
847
7932
Z01.8
ICD-10 Finland
Other specified special examinations
1.6
7.4
188
1263
KCW98
NOMESCO Finland
Other transluminal endoscopic operation on bladder
+∞
7.3
7
*
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.5
7.3
291
2166
H30.2
ICD-10 Finland
Posterior cyclitis
15.9
7.2
11
7
Z93.5
ICD-10 Finland
Cystostomy status
30.3
7.2
9
*
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
3.7
7.1
22
61
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
4.0
6.9
19
48
NA1CM
NOMESCO Finland
Cervical spine extensive MRI examination with 3 Tesla magnet
13.9
6.9
11
8
RF210, ,
NOMESCO Finland
2.8
6.8
33
121
N07AA03
ATC
distigmine; systemic
40.4
6.8
8
*
RF432, ,
NOMESCO Finland
40.4
6.8
8
*
N02BF02
ATC
pregabalin; oral
2.1
6.7
60
292
RS222, ,
NOMESCO Finland
6.0
6.6
17
29
OAB43, ,
SPAT
0.7
6.6
248
3257
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.6
6.5
191
1326
SFA20
NOMESCO Finland
Two-surface restoration
1.4
6.5
564
4839
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
3.0
6.5
28
96
G04BD
ATC
Drugs for urinary frequency and incontinence
70.3
6.4
7
*
N30
ICD-10 Finland
Cystitis
1.9
6.4
81
446
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
14.4
6.4
10
7
Z73.6
ICD-10 Finland
Limitation of activities due to disability
8.2
6.3
13
16
R19.5
ICD-10 Finland
Other faecal abnormalities
5.2
6.3
18
35
J01MA06
ATC
norfloxacin; oral
1.7
6.3
111
676
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
18.2
6.3
9
5
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
+∞
6.3
6
*
G37.0
ICD-10 Finland
Diffuse sclerosis
+∞
6.3
6
*
RF433, ,
NOMESCO Finland
26.9
6.2
8
*
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.0
6.2
17
43
CS494
NOMESCO Finland
Other visual field testing
3.6
6.2
20
57
C03CA01
ATC
furosemide; systemic
1.7
6.2
104
626
R13
ICD-10 Finland
Dysphagia
2.2
6.1
51
241
J05AB11
ATC
valaciclovir; oral
1.7
6.1
128
817
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
3.8
6.1
18
48
H52.1
ICD-10 Finland
Myopia
2.3
6.1
44
196
G04BD01
ATC
emepronium; systemic
8.7
6.1
12
14
R60.0
ICD-10 Finland
Localized oedema
1.9
6.1
73
396
WX320
NOMESCO Finland
Spinalanesthesy
0.5
6.0
71
1238
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
122
10
141.15
243.54
2.8
1.4
—
—
—
0
0
165
131
15.22
174.82
1.2
1.1
—
—
—
0
0
722
3452
6.70
129.55
14.4
6.1
9.46
8.01
%
33.69
713
3273
717
3428
6.54
128.02
14.3
5.8
3.09
2.77
%
4.19
708
3240
755
3793
7.41
126.61
14.6
5.8
1.65
1.97
e9/l
2.15
727
3450
753
3807
7.24
124.30
14.7
6.1
0.18
0.18
e9/l
0.01
724
3433
725
3589
6.42
121.40
14.3
5.8
26.31
29.28
%
11.64
716
3414
720
3554
6.30
120.67
13.8
5.6
58.50
56.65
%
4.35
711
3373
82
48
18.71
100.88
4.3
2.4
0.24
0.18
e9/l
2.04
71
42
83
50
18.20
100.71
4.3
2.5
404.00
536.58
e6/l
0.93
71
43
754
4192
6.13
100.22
15.1
8.8
3.35
3.98
e9/l
21.43
728
3704
153
248
7.24
93.41
1.8
1.6
420.09
0.02
iu/ml
—
5
36
71
45
17.05
83.78
2.7
2.1
—
—
—
0
0
342
1200
4.00
83.31
4.4
2.2
4.64
7.96
e6/l
3.57
320
1077
50
15
35.25
78.70
1.3
1.1
—
—
—
0
0
421
1763
3.63
77.58
6.1
2.6
15.55
50.91
e6/l
2.72
370
1325
582
3007
3.69
76.51
2.4
2.3
98.31
74.87
nmol/l
44.78
553
2816
388
1599
3.52
72.29
5.3
2.6
0.11
0.35
e6/l
3.82
333
1182
208
559
4.55
71.89
3.7
2.6
9.50
10.33
g/l
3.59
199
513
172
431
4.70
64.54
3.5
1.7
0.95
1.36
g/l
3.68
167
404
54
44
13.00
55.14
1.1
1.1
1391.70
1716.32
miu/ml
0.90
54
44
250
941
3.30
51.35
4.8
2.3
0.97
0.96
e6/l
0.01
152
501
236
870
3.33
50.03
4.9
2.4
5.20
3.61
e6/l
0.70
138
431
39
25
16.27
45.39
5.5
2.8
—
—
—
0
0
683
4599
3.06
45.30
9.5
3.5
28.60
693.44
e6/l
—
10
50
71
146
5.20
33.10
4.6
4.4
61.06
57.73
%
1.26
71
146
70
143
5.23
32.88
4.6
4.0
3.40
4.29
e9/l
3.72
70
143
533
3628
2.16
27.20
7.1
2.9
0.00
0.01
estimate
1.06
124
657
529
3592
2.16
27.14
9.6
4.1
0.01
0.00
estimate
0.38
122
685
528
3590
2.15
26.90
7.1
2.9
0.00
0.00
estimate
0.50
126
707
37
49
7.83
26.49
3.4
2.7
49.72
46.15
%
0.51
25
24
29
6
49.85
24.40
1.2
1.2
—
—
—
0
0
478
3394
1.88
18.70
4.6
5.8
9.36
10.09
umol/l
1.61
461
3210
654
7508
0.52
15.59
3.3
3.7
1.52
1.50
mmol/l
0.43
597
7191
620
7233
0.53
15.57
3.0
3.4
1.24
1.26
mmol/l
0.29
571
6899
661
7531
0.53
14.38
3.3
3.7
4.86
4.86
mmol/l
0.08
617
7242
782
6790
2.22
14.13
21.8
12.6
14.19
14.28
%
0.19
777
6695
876
8069
5.50
13.75
17.2
8.7
27.13
26.22
u/l
1.10
868
7890
673
7591
0.54
13.10
3.5
3.9
2.92
2.94
mmol/l
0.17
618
7260
73
287
2.68
12.96
1.4
1.3
—
—
—
0
0
22
19
11.84
12.36
2.0
2.2
—
—
—
0
0
93
435
2.27
11.36
2.8
1.7
—
—
—
0
0
249
1681
1.67
9.96
2.3
1.4
1.99
2.20
g/l
1.73
179
1114
107
575
1.98
9.10
2.4
2.1
5263.29
4111.50
u/l
0.10
34
240
648
5621
1.56
7.84
4.7
2.9
42.21
38.66
u/l
0.54
629
5408
369
2853
1.50
7.80
8.4
2.9
—
—
—
0
0
23
69
3.40
6.59
1.0
1.1
—
—
—
0
0
817
7599
1.88
6.59
12.4
10.5
18.96
19.19
mg/l
0.06
593
5797
609
5294
1.47
6.59
5.3
6.9
72.40
73.63
u/l
0.45
575
5030
333
2607
1.44
6.24
3.6
3.2
27.71
29.46
u/l
0.68
321
2509
51
242
2.17
6.07
1.5
1.5
—
—
—
0
0
245
1841
1.46
5.60
9.5
3.2
0.00
0.00
estimate
1.08
125
675
23
79
2.96
5.33
2.8
2.8
0.46
1.22
%
1.73
23
71
5
0
+∞
5.21
1.4
0.0
—
—
—
0
0
292
2300
1.40
5.06
1.7
1.7
98.13
98.79
pmol/l
0.08
148
1251
24
91
2.68
4.68
1.0
1.1
—
—
—
0
0
44
225
2.01
4.38
1.3
1.4
26.62
24.76
u/l
0.14
35
187
598
6551
0.74
4.30
3.6
4.3
36.86
38.12
mmol/mol
3.82
552
6254
101
1473
0.65
4.16
1.2
1.3
1.80
10.13
u/ml
5.03
42
643
786
7392
1.53
4.11
11.3
10.5
139.87
139.63
mmol/l
2.56
773
7224
787
7415
1.52
3.95
11.3
10.6
3.90
3.92
mmol/l
1.35
768
7227
35
171
2.09
3.95
1.3
1.6
11.68
10.84
e6/l
0.05
28
135
35
171
2.09
3.95
1.4
1.7
455.46
140.36
e6/l
0.56
28
141
121
848
1.49
3.87
1.7
1.8
—
—
—
0
0
24
102
2.39
3.76
1.0
1.1
—
—
—
0
0
754
7063
1.43
3.72
11.3
8.8
96.40
91.30
ml/min/173m2
11.22
641
5786
882
8613
2.95
3.46
26.3
15.6
40.91
40.55
%
2.13
835
8238
426
3718
1.28
3.28
3.8
4.3
6.03
6.39
mmol/l
5.02
395
3417
753
7096
1.39
3.19
5.4
4.8
1.67
2.06
mu/l
1.03
717
6764
882
8630
2.79
3.11
26.4
15.6
4.52
4.55
e12/l
1.45
877
8476
664
7075
0.76
3.10
3.2
3.6
5.58
5.69
mmol/l
1.68
608
6684
216
1744
1.31
2.98
1.9
2.1
128.71
153.73
u/l
0.45
208
1661
300
2544
1.27
2.82
4.1
4.7
37.24
36.97
g/l
0.42
276
2410
10
28
3.60
2.79
1.5
2.8
—
—
—
0
0
82
569
1.49
2.79
1.7
1.6
—
—
—
0
0
283
2390
1.27
2.74
5.5
7.5
1.06
1.08
inr
0.38
81
784
76
1080
0.68
2.73
1.5
1.6
—
—
—
0
0
157
1230
1.34
2.66
1.4
1.4
21.18
20.89
nmol/l
0.08
135
1107
187
1505
1.31
2.62
8.1
3.1
1.02
1.02
kg/l
0.22
25
191
82
580
1.46
2.55
1.7
1.7
—
—
—
0
0
119
1539
0.74
2.46
1.3
1.3
10.61
26.25
iu/ml
7.51
32
526
103
780
1.36
2.19
2.2
2.5
4.28
5.97
umol/l
1.88
87
662
32
517
0.60
2.11
1.2
1.5
—
—
—
0
0
606
6433
0.82
2.03
3.6
3.7
—
—
—
0
0
12
51
2.37
1.95
1.8
2.7
49.42
56.00
%
0.34
12
46
10
39
2.58
1.94
1.0
1.1
—
—
—
0
0
20
106
1.91
1.92
1.4
1.3
—
—
—
0
0
20
106
1.91
1.92
1.4
1.3
—
—
—
0
0
144
1752
0.79
1.88
4.6
3.1
8.14
8.05
mmol/l
0.08
132
1561
34
523
0.64
1.84
2.1
2.2
80.92
77.34
ml/min/173m2
0.18
12
206
27
436
0.61
1.80
1.5
1.7
4.54
3.76
mg/l
0.18
16
308
106
838
1.30
1.72
1.4
1.6
1095.49
1190.30
nmol/l
0.28
82
667
24
392
0.60
1.69
1.7
1.9
—
—
—
0
0
16
83
1.94
1.65
1.1
1.2
—
—
—
0
0
575
5396
1.18
1.64
2.8
3.7
9.06
9.30
mm/h
0.25
542
5107
23
137
1.70
1.56
1.6
6.8
—
223.50
—
0
20
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
44
2.29
1.56
1.0
1.1
—
—
—
0
0
13
64
2.05
1.54
1.2
1.4
—
—
—
0
0
19
319
0.59
1.51
1.5
1.7
—
—
—
0
0
124
1018
1.25
1.51
2.9
3.1
717.53
289.34
ng/l
0.40
68
567
305
3370
0.86
1.42
2.3
2.4
—
—
—
0
0
80
628
1.30
1.40
2.3
2.3
51.20
38.34
u/l
0.24
61
525
56
741
0.74
1.39
1.9
2.1
313.06
372.13
nmol/l
1.70
51
692
14
74
1.91
1.39
1.2
1.4
231.83
456.42
pmol/l
2.42
14
65
11
54
2.05
1.33
1.0
1.1
—
—
—
0
0
19
113
1.70
1.32
1.5
3.2
—
2577.09
—
0
11
9
43
2.10
1.30
1.2
1.3
—
—
—
0
0
60
769
0.76
1.22
1.3
1.5
—
—
—
0
0
6
26
2.32
1.19
1.3
1.5
—
—
—
0
0
6
26
2.32
1.19
1.3
1.5
—
—
—
0
0
6
26
2.32
1.19
1.0
1.1
88.17
97.62
%
—
6
26
132
1542
0.83
1.18
5.4
3.8
6.48
9.66
mg/mmol
0.65
92
990
354
3825
0.88
1.15
2.7
2.8
97.74
82.06
ug/l
0.76
330
3636
5
21
2.39
1.09
1.0
1.6
—
—
—
0
0
5
21
2.39
1.09
1.0
1.6
—
—
—
0
0
53
410
1.31
1.07
1.2
1.3
163.24
236.23
miu/ml
0.84
21
210
81
982
0.81
1.06
1.6
1.8
—
—
—
0
0
74
602
1.25
1.02
4.4
6.6
105.51
104.45
mmol/l
1.71
74
602
25
347
0.71
0.90
1.5
2.1
4.81
7.23
ug/l
0.50
20
322
9
152
0.59
0.89
1.3
1.5
—
—
—
0
0
232
2114
1.13
0.87
2.8
2.7
75.73
28.97
ng/l
0.55
118
1016
149
1676
0.87
0.86
1.7
2.2
1394.00
4587.72
umol/l
1.49
137
1521
69
828
0.82
0.85
1.3
1.3
32.65
26.67
iu/l
0.66
60
715
312
2900
1.12
0.84
5.7
6.2
1.22
1.22
mmol/l
0.20
260
2492
28
374
0.74
0.81
1.4
1.5
—
—
—
0
0
33
428
0.76
0.79
1.2
1.4
—
—
—
0
0
8
48
1.67
0.79
1.4
1.1
—
—
—
0
0
62
745
0.82
0.78
1.5
1.8
—
—
—
0
0
56
680
0.81
0.78
5.4
5.3
—
—
—
0
0
33
427
0.76
0.78
1.2
1.4
—
—
—
0
0
36
460
0.77
0.77
2.9
4.3
4.65
17.83
ug/l
0.68
31
355
33
426
0.77
0.77
1.2
1.4
—
—
—
0
0
216
1976
1.12
0.77
1.2
1.3
0.77
1.61
u/ml
1.31
53
571
276
2562
1.11
0.76
4.8
5.5
1.22
1.22
mmol/l
0.28
249
2381
33
425
0.77
0.76
1.2
1.4
—
—
—
0
0
14
91
1.55
0.75
1.0
1.6
—
—
—
0
0
36
457
0.78
0.74
1.1
1.5
—
—
—
0
0
9
55
1.64
0.73
1.4
2.2
106.44
105.78
mmol/l
—
9
55
40
500
0.79
0.73
1.3
1.5
—
—
—
0
0
5
25
2.01
0.72
6.8
2.3
—
—
—
0
0
17
117
1.46
0.72
1.4
2.0
—
1600.00
—
0
5
13
193
0.67
0.70
1.5
1.3
278.03
326.55
ug/g
—
6
103
42
518
0.80
0.69
1.6
1.6
281.36
304.45
mu/l
0.26
36
464
18
249
0.72
0.67
1.2
1.2
—
—
—
0
0
5
28
1.79
0.66
1.2
1.4
—
—
—
0
0
24
180
1.34
0.65
1.3
1.8
—
—
—
0
0
5
29
1.73
0.64
1.2
1.4
—
—
—
0
0
38
467
0.81
0.62
1.4
1.5
—
—
—
0
0
52
436
1.20
0.60
2.6
3.6
1.85
1.91
mmol/l
0.04
43
364
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
21
157
1.35
0.59
1.7
2.2
191.71
258.20
ug/l
0.23
21
142
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
33
265
1.25
0.57
1.3
1.3
—
—
—
0
0
5
87
0.57
0.56
1.2
1.1
—
—
—
0
0
26
203
1.29
0.56
1.7
1.8
—
—
—
0
0
17
124
1.38
0.56
4.1
3.3
32.80
23.64
mg/l
—
6
81
169
1830
0.91
0.54
1.6
1.6
1.32
1.42
mmol/l
0.68
146
1612
13
182
0.71
0.54
1.8
2.8
1.19
1.33
mg/l
0.46
13
171
21
270
0.77
0.52
1.3
1.5
—
—
—
0
0
19
247
0.76
0.51
1.2
1.2
—
—
—
0
0
6
41
1.47
0.50
1.7
2.9
895.50
714.34
u/ml
—
6
41
67
589
1.15
0.48
3.3
3.6
4.47
4.52
pmol/l
0.20
61
532
28
227
1.24
0.47
1.6
2.6
0.75
0.67
%
0.68
28
227
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
103
1.36
0.45
1.8
4.5
0.32
0.34
u/ml
—
5
49
51
442
1.16
0.44
2.6
3.0
1.23
1.23
mmol/l
0.09
43
385
10
69
1.45
0.44
1.2
1.4
—
—
—
0
0
45
522
0.85
0.44
1.7
2.3
0.55
0.63
ug/l
0.52
29
248
101
920
1.11
0.42
2.0
2.3
14.65
14.40
umol/l
0.13
96
865
5
32
1.57
0.42
1.2
1.3
—
—
—
0
0
5
32
1.57
0.42
1.2
1.2
—
—
—
0
0
79
710
1.12
0.42
3.6
3.5
30.11
31.84
%
0.70
62
539
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
3.9
—
—
—
0
0
0
15
0.00
0.41
0.0
3.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
1.19
—
0
15
0
17
0.00
0.40
0.0
1.3
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
102
1112
0.91
0.40
1.7
2.4
131.47
97.75
ug/g
0.28
72
895
16
204
0.78
0.39
1.0
1.1
0.63
1.92
u/ml
—
6
97
88
965
0.90
0.38
2.2
2.4
2.42
2.42
mmol/l
0.21
74
850
12
159
0.75
0.38
1.1
1.1
—
—
—
0
0
42
483
0.86
0.38
1.5
1.5
—
—
—
0
0
9
67
1.35
0.38
1.9
1.2
—
—
—
0
0
9
67
1.35
0.38
1.9
1.2
—
—
—
0
0
9
68
1.33
0.37
1.9
1.2
—
—
—
0
0
9
68
1.33
0.37
1.9
1.2
—
—
—
0
0
9
68
1.33
0.37
1.9
1.2
—
—
—
0
0
26
311
0.83
0.37
5.3
3.1
5.18
5.15
kpa
0.05
26
300
17
134
1.27
0.37
2.2
2.7
—
—
—
0
0
29
244
1.19
0.36
2.8
2.0
6.78
5.05
iu/l
0.43
14
94
9
126
0.71
0.35
1.2
1.2
—
—
—
0
0
55
491
1.13
0.34
1.1
1.0
—
—
—
0
0
6
45
1.34
0.33
1.0
1.1
77.88
160.75
iu/ml
—
6
45
6
87
0.69
0.33
1.0
1.5
—
—
—
0
0
6
87
0.69
0.33
1.0
1.5
—
—
—
0
0
6
88
0.68
0.33
1.2
1.2
12.27
11.69
u/l
—
6
75
12
153
0.78
0.31
1.0
1.0
—
0.08
—
0
42
26
221
1.18
0.31
1.9
2.0
—
—
—
0
0
7
100
0.70
0.30
5.0
2.6
8.44
8.40
kpa
—
7
100
7
55
1.27
0.30
1.0
1.2
—
2.40
—
0
5
14
173
0.81
0.28
1.5
2.2
4.52
4.79
umol/l
—
9
128
81
749
1.09
0.28
2.0
2.4
24.87
24.22
%
0.16
66
645
28
242
1.16
0.28
1.1
1.1
—
—
—
0
0
148
1560
0.94
0.28
1.9
2.1
2.59
2.80
mg/l
0.47
124
1364
8
63
1.27
0.28
1.5
1.2
—
—
—
0
0
63
687
0.91
0.27
2.3
3.1
21.65
21.91
%
0.04
20
213
9
121
0.74
0.27
1.1
1.7
—
—
—
0
0
9
121
0.74
0.27
1.1
1.7
—
—
—
0
0
12
149
0.80
0.26
1.0
1.1
—
—
—
0
0
6
82
0.73
0.24
1.2
1.5
—
—
—
0
0
56
514
1.10
0.24
6.7
9.7
1.11
1.00
mmol/l
0.08
41
398
17
200
0.85
0.23
5.8
3.1
24.47
24.68
mmol/l
0.10
17
190
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
1.17
—
0
12
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
12
145
0.83
0.21
1.1
1.3
—
—
—
0
0
11
89
1.24
0.21
1.2
1.4
—
—
—
0
0
111
1055
1.06
0.20
2.1
2.8
594.02
633.32
ng/l
0.08
89
858
0
14
0.00
0.20
0.0
1.0
—
0.14
—
0
9
19
165
1.15
0.19
1.6
1.6
—
—
—
0
0
13
109
1.20
0.18
1.2
1.7
—
—
—
0
0
15
128
1.17
0.18
1.2
1.2
—
—
—
0
0
20
227
0.88
0.18
1.2
1.1
2.32
2.26
u/ml
—
7
107
21
185
1.14
0.18
1.2
1.2
—
—
—
0
0
15
174
0.86
0.18
1.2
1.2
—
—
—
0
0
23
205
1.13
0.17
1.4
1.6
—
—
—
0
0
5
70
0.71
0.16
1.0
1.3
68.00
71.03
umol/l
—
5
70
10
120
0.83
0.16
1.9
4.0
29.10
33.38
umol/l
—
10
111
18
158
1.14
0.16
1.2
1.7
—
—
—
0
0
168
1734
0.96
0.16
1.5
1.7
0.57
0.81
mg/l
2.53
123
1285
90
943
0.95
0.16
2.7
3.4
0.85
0.82
mmol/l
1.04
85
902
24
216
1.11
0.15
2.0
2.3
8.69
10.10
mg/l
0.52
24
200
6
78
0.77
0.15
1.5
1.6
—
—
—
0
0
6
78
0.77
0.15
1.5
1.6
—
—
—
0
0
6
79
0.76
0.15
1.5
1.6
—
—
—
0
0
6
79
0.76
0.15
1.5
1.6
—
—
—
0
0
6
79
0.76
0.15
1.5
1.6
—
—
—
0
0
6
79
0.76
0.15
1.5
1.6
—
—
—
0
0
6
80
0.75
0.15
1.5
1.4
33.48
31.99
nmol/l
—
6
64
28
307
0.91
0.15
1.7
1.9
—
—
—
0
0
157
1621
0.96
0.15
2.0
2.0
—
—
—
0
0
213
2078
1.03
0.14
2.1
2.5
53.43
56.29
u/l
0.85
202
1955
24
264
0.91
0.14
1.5
1.4
69.20
104.10
pmol/l
0.39
24
258
36
334
1.08
0.14
1.7
1.5
—
—
—
0
0
12
138
0.87
0.13
1.0
1.3
—
—
—
0
0
18
162
1.11
0.12
1.2
1.6
—
—
—
0
0
11
95
1.16
0.11
3.7
2.1
16.10
16.76
%
—
6
50
79
759
1.04
0.11
1.3
1.2
218.06
155.19
iu/ml
0.44
33
307
33
308
1.07
0.11
2.1
2.6
78.85
88.28
ng/l
0.15
27
267
200
2043
0.97
0.11
1.5
1.6
—
—
—
0
0
140
1438
0.97
0.11
1.7
1.9
—
—
—
0
0
126
1227
1.03
0.10
1.4
1.5
446.40
38649079.99
pmol/l
1.81
114
1110
5
47
1.06
0.09
1.0
1.4
7.20
6.54
u/l
—
5
39
5
47
1.06
0.09
9.4
3.3
39620.00
38265.96
ug/l
—
5
47
157
1602
0.98
0.08
1.8
2.0
—
—
—
0
0
206
2026
1.02
0.08
1.5
1.5
—
—
—
0
0
6
72
0.83
0.07
1.0
1.1
—
—
—
0
0
10
89
1.12
0.07
1.1
1.4
—
—
—
0
0
43
413
1.04
0.06
4.1
3.8
77.39
78.39
ng/l
0.03
36
385
8
95
0.84
0.06
1.6
1.4
—
—
—
0
0
11
99
1.11
0.06
2.3
2.3
—
—
—
0
0
15
162
0.92
0.06
2.6
1.9
—
—
—
0
0
18
168
1.07
0.06
1.3
1.1
0.65
2.45
u/ml
—
6
90
30
287
1.05
0.05
1.4
2.1
—
—
—
0
0
22
232
0.95
0.05
1.1
1.3
—
2.74
—
0
27
11
119
0.92
0.04
1.2
1.4
—
—
—
0
0
18
171
1.05
0.03
1.3
1.2
303.10
251.56
u/ml
—
10
109
64
628
1.02
0.03
1.2
1.3
75.85
191.10
u/ml
3.50
57
581
31
319
0.97
0.02
1.2
1.3
12.14
11.46
u/l
0.10
25
262
87
859
1.01
0.02
2.6
3.2
1.36
1.42
ug/l
0.12
80
793
616
6147
1.01
0.02
4.6
4.2
14.39
14.31
pmol/l
0.39
570
5817
10
93
1.08
0.02
1.5
2.0
—
—
—
0
0
207
2078
0.99
0.01
2.5
3.3
2.35
2.35
mmol/l
0.04
184
1905
10
102
0.98
0.00
1.2
1.4
—
—
—
0
0
22
222
0.99
0.00
4.2
2.3
3.11
3.54
g/l
0.73
22
211
56
562
1.00
0.00
2.4
2.5
—
—
—
0
0
10
97
1.03
0.00
1.3
1.4
—
—
—
0
0
10
103
0.97
0.00
1.5
1.3
—
—
—
0
0
39
393
0.99
0.00
1.5
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
56
0.89
0.00
1.0
1.1
—
—
—
0
0
6
65
0.92
-0.00
2.2
1.5
—
—
—
0
0
9
92
0.98
-0.00
1.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
-0.00
2.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
59
1.02
-0.00
1.0
1.2
—
—
—
0
0
7
72
0.97
-0.00
4.9
3.3
17.00
50.39
u/ml
—
7
72
5
58
0.86
-0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
71
0.99
-0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.3
—
28.50
—
0
6
5
51
0.98
-0.00
1.2
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
3.38
—
0
5
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_INTERFERONBETA1A – Use of interferon beta-1a
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).